Clinical trials: Obstructive Pulmonary Disease
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease
The functional, social, and economic burden of chronic obstructive lung disease (COPD) on the healthcare system is extraordinary.
- Trial name
- TADA-PHILD (NCT01862536)
- Testing
- Tadalafil
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- VA Office of Research and Development
Airway Inflammation, Asthma
A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults
Purpose: To determine the efficacy of 1400 mg gamma tocopherol-enriched supplement for mitigating inhaled wood smoke particle-induced airway inflammation in healthy adults with no more than mild asthma.
- Trial name
- SmokeyT (NCT03444298)
- Testing
- Gamma Tocopherol
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI; PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with placebo.
- Trial name
- NCT02343458
- Testing
- GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001)
- Where
- 166 sites in United States, China and 9 more
- Volunteers
- 1,756 people
- Sponsor
- Pearl Therapeutics, Inc.
Respiratory Syncytial Virus Bronchiolitis
Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
This is a prospective, multicenter, observational study in participants who completed the 24-week, placebo-controlled MK-0476 Protocol 272 (NCT00076973) study of montelukast in the treatment of respiratory symptoms subsequent to…
- Trial name
- NCT01140048
- Volunteers
- 343 people
- Sponsor
- Organon and Co
Asthma
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an…
- Trial name
- SWIFT-1 (NCT04719832)
- Testing
- GSK3511294 (Depemokimab)
- Where
- 123 sites in United States, Canada and 10 more
- Volunteers
- 395 people
- Sponsor
- GlaxoSmithKline
Asthma
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway…
- Trial name
- NCT02712047
- Testing
- Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg)
- Where
- New Zealand
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic…
- Trial name
- NCT00452348
- Testing
- Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
- Where
- 81 sites in United States, Argentina and 3 more
- Volunteers
- 628 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
The study will include 60 healthy subjects (ex-smoker without any airflow limitation), 125 COPD GOLD (global initiative for chronic obstructive lung disease) I , 125 COPD GOLD II, 125 COPD GOLD III and up to 20 patients with COPD…
- Trial name
- NCT02719184
- Where
- 51 sites in United States, Belgium and 10 more
- Volunteers
- 463 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasm
- Trial name
- PICSI-H (NCT04281784)
- Testing
- EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 2,512 people
- Sponsor
- University of Washington
Asthma
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total…
- Trial name
- NCT02554786
- Testing
- Indacaterol acetate/Mometasone furoate, Mometasone furoate, Salmeterol xinafoate/fluticasone propionate
- Where
- 388 sites in United States, Bulgaria and 22 more
- Volunteers
- 2,216 people
- Sponsor
- Novartis Pharmaceuticals
COPD, Emphysema
Bronchitis and Emphysema Advice and Training to Reduce Hospitalization
EXECUTIVE SUMMARY: Purpose: To evaluate the efficacy and cost-effectiveness of a novel intervention incorporating self-management education, an action plan, and case-management to decrease the risk of hospitalizations due to…
- Trial name
- BREATH (NCT00395083)
- Testing
- COPD Self-management Education
- Where
- 22 sites in United States
- Volunteers
- 426 people
- Sponsor
- US Department of Veterans Affairs
Chronic Obstructive Pulmonary Disease (COPD)
A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the effect of aclidinium bromide compared with placebo in improving dilatation of the airways (bronchodilation), symptoms of chronic obstructive pulmonary disease (COPD), sleep quality and…
- Trial name
- NCT02153489
- Testing
- Aclidinium bromide
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Smoking
Electronic Proactive Outreach for Smokers With COPD
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases, with 90% of cases directly attributable to smoking. Unfortunately, many patients continue to smoke and have an urgent need to quit.
- Trial name
- NCT04462289
- Testing
- Proactive Outreach
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- VA Office of Research and Development
Asthma
Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy
The objective of this study is to compare healthcare utilization and costs in Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a…
- Trial name
- NCT01347060
- Testing
- fluticasone propionate/salmeterol xinafoate combination, inhaled corticosteroids
- Volunteers
- 17,448 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
This is a multi-centre, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control.
- Trial name
- NCT02281318
- Testing
- Mepolizumab, SOC
- Where
- 144 sites in United States, Argentina and 17 more
- Volunteers
- 556 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and…
- Trial name
- NCT01899742
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Where
- 64 sites in United States, Argentina and 8 more
- Volunteers
- 497 people
- Sponsor
- GlaxoSmithKline
Asthma
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.
- Trial name
- NCT02031640
- Testing
- Beclomethasone dipropionate, Albuterol/salbutamol
- Where
- 131 sites in United States, Germany and 2 more
- Volunteers
- 1,113 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life.
- Trial name
- NCT01388920
- Testing
- Tesamorelin
- Volunteers
- 3 people
- Sponsor
- Theratechnologies
Asthma
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
The aim of the study is to assess and compare efficacy and safety of BI 54903 at 3 doses twice daily (b.i.d.) and fluticasone propionate hydrofluoroalkane metered dose inhaler (HFA MDI) at a dose of 88 mcg b.i.d and placebo…
- Trial name
- NCT01397162
- Testing
- Fluticasone propionate, BI 54903
- Where
- 41 sites in United States
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00642616
- Testing
- Technosphere® Insulin, Usual Care
- Where
- 21 sites in United States, Russia and 1 more
- Volunteers
- 34 people
- Sponsor
- Mannkind Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.